WallStSmart

Sabra Healthcare REIT Inc (SBRA)vsVentas Inc (VTR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ventas Inc generates 649% more annual revenue ($6.11B vs $815.66M). SBRA leads profitability with a 19.2% profit margin vs 4.3%. VTR appears more attractively valued with a PEG of 1.74. SBRA earns a higher WallStSmart Score of 59/100 (C).

SBRA

Buy

59

out of 100

Grade: C

Growth: 5.3Profit: 7.0Value: 6.0Quality: 5.5
Piotroski: 3/9Altman Z: 0.39

VTR

Buy

51

out of 100

Grade: C-

Growth: 7.3Profit: 4.5Value: 3.3Quality: 4.0
Piotroski: 4/9Altman Z: 0.43
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SBRAUndervalued (+84.2%)

Margin of Safety

+84.2%

Fair Value

$124.38

Current Price

$18.46

$105.92 discount

UndervaluedFair: $124.38Overvalued
VTROvervalued (-9.8%)

Margin of Safety

-9.8%

Fair Value

$77.07

Current Price

$79.09

$2.02 premium

UndervaluedFair: $77.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SBRA3 strengths · Avg: 8.7/10
Operating MarginProfitability
31.4%10/10

Strong operational efficiency at 31.4%

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
21.7%8/10

Revenue surging 21.7% year-over-year

VTR2 strengths · Avg: 8.0/10
Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
21.9%8/10

Revenue surging 21.9% year-over-year

Areas to Watch

SBRA4 concerns · Avg: 3.0/10
P/E RatioValuation
29.7x4/10

Moderate valuation

Return on EquityProfitability
5.6%3/10

ROE of 5.6% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

VTR4 concerns · Avg: 3.0/10
PEG RatioValuation
1.744/10

Expensive relative to growth rate

Return on EquityProfitability
2.0%3/10

ROE of 2.0% — below average capital efficiency

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

P/E RatioValuation
153.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : SBRA

The strongest argument for SBRA centers on Operating Margin, Price/Book, Revenue Growth. Profitability is solid with margins at 19.2% and operating margin at 31.4%. Revenue growth of 21.7% demonstrates continued momentum.

Bull Case : VTR

The strongest argument for VTR centers on Price/Book, Revenue Growth. Revenue growth of 21.9% demonstrates continued momentum.

Bear Case : SBRA

The primary concerns for SBRA are P/E Ratio, Return on Equity, Piotroski F-Score.

Bear Case : VTR

The primary concerns for VTR are PEG Ratio, Return on Equity, Profit Margin. A P/E of 153.8x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

VTR carries more volatility with a beta of 0.73 — expect wider price swings.

VTR is growing revenue faster at 21.9% — sustainability is the question.

SBRA generates stronger free cash flow (98M), providing more financial flexibility.

Monitor REIT - HEALTHCARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SBRA scores higher overall (59/100 vs 51/100), backed by strong 19.2% margins and 21.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sabra Healthcare REIT Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

As of September 30, 2020, Sabra's investment portfolio included 425 real estate properties held for investment (consisting of (i) 287 skilled nursing / transitional care facilities, (ii) 64 senior housing communities (?

Ventas Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Ventas, Inc. is a real estate investment trust specializing in the ownership and management of health care facilities in the United States, Canada and the United Kingdom.

Want to dig deeper into these stocks?